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ABSTRACT
Pathogens have developed sophisticated strategies to evade the immune response, among which
manipulation of host cellular epigenetic mechanisms plays a prominent role. In the last decade,
modulation of histone acetylation in host cells has emerged as an efficient strategy of bacterial
immune evasion. Virulence factors and metabolic products of pathogenic microorganisms alter
expression and activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs) to
suppress transcription of host defense genes through epigenetic changes in histone acetylation
marks. This new avenue of pathogen–host interactions is particularly important in light of intro-
duction of HDAC inhibitors into clinical practice. Considerable effort is currently being applied to
better understand the effects of HDAC inhibitors on the quality of immune responses to patho-
gens and to characterize the therapeutic potential of these compounds in microbial infections. In
this review, we will discuss the recently discovered mechanisms utilized by bacteria to facilitate
their survival within infected hosts through subversion of the host acetylation system and the
effects of acetylation modulators, including HDAC inhibitors and bromodomain-containing BET
protein inhibitors, on innate immune responses against microbial pathogens. Integration of these
two lines of experimental evidence provides critical information on the perspectives of epigenetic
therapies targeting protein acetylation in infectious diseases.
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Introduction
Infectious diseases cause more than 10 million deaths
per year worldwide and remain one of the main causes
of morbidity and mortality, particularly in the developing
world (GBD 2015 Disease and Injury Incidence and
Prevalence Collaborators 2016). There is an urgent need
to develop new treatment strategies for bacterial infec-
tions given the unchecked global rise in the incidence of
antibiotic-resistant infections, coupled with an antibiotic
pipeline that has produced few novel antibiotics in the
last 30 years. One approach that could potentially cir-
cumvent the problem of antibiotic resistance involves
host-directed therapy, which aims to promote the
pathogen elimination by boosting immune responses, in
particular the host defense pathways that are subverted
by pathogens for their own survival advantage. While it
is well established how pathogens can hijack cellular
responses through disruption of intracellular signaling
pathways and transcription factor activation, the obser-
vation that bacteria may exert subversive effects on host
inflammatory responses by dysregulating specific
epigenetic mechanisms has opened a new area in the
biology of host–microbe interactions.
Acetylation in epigenetic regulation: HATs,
HDACs, BET proteins, and HDAC inhibitors
Epigenetic mechanisms are most commonly defined as
stable changes in gene expression profile or cellular
phenotype that are caused by modifications of chromo-
somes without alterations in the DNA sequence.
Although the original definition of epigenetics covered
only heritable changes in chromosome structure
(Berger et al. 2009), it is now commonly extended to
reversible modifications of chromatin that are dynamic-
ally induced by environmental factors. The cellular
mechanisms responsible for epigenetic regulation
include methylation of chromosomal DNA and a net-
work of post-translational modifications of histone pro-
teins. DNA methylation typically occurs at CpG
dinucleotides and causes transcriptional repression
either by recruitment of co-repressors or through dis-
ruption of transcription factor binding to DNA
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(Jones 2012). In contrast, post-translational histone
modifications, among which acetylation, methylation,
and phosphorylation are the best characterized, either
suppress or enhance transcription by modulating the
availability of gene promoters for transcription factors
and RNA polymerase II (Gardner et al. 2011).
Histone proteins are acetylated on their N-terminal
lysine residues by histone acetyltransferases (HATs). This
process leads to opening of chromatin structure,
increased accessibility of gene promoters, and recruit-
ment of transcriptional regulators recognizing acety-
lated lysines, such as bromodomain-containing BET
(bromodomain and extra-terminal) proteins, and is gen-
erally associated with enhanced transcription. Histone
deacetylases (HDACs) counteract the activity of HATs
and remove acetyl groups from histones, leading to ter-
mination of transcriptional processes (Verdin and Ott
2015). Four classes of HDACs are expressed in mam-
mals: class I (HDACs 1–3 and 8), class II (HDACs 4–7, 9
and 10), and class IV (HDAC11) are zinc-dependent
enzymes, whereas the activity class III HDACs (sirtuins
Sirt1–7) is NAD-dependent (de Ruijter et al. 2003).
Although required for transcriptional activation, histone
acetylation alone is not sufficient for gene induction
and thus global or promoter-specific increases in the
acetylation status of histone tails are not always directly
translated into enhanced transcription (Wang et al.
2009). This is exemplified by transcriptomic studies of
HDAC inhibitors in cancer cell lines, in which compar-
able numbers of genes were up- and downregulated,
despite global histone hyperacetylation (Glaser et al.
2003; Peart et al. 2005). Recent advances in mass spec-
trometric technologies have also revealed that protein
acetylation is not restricted to histones; in fact, the
prevalence and importance of acetylation is comparable
to that of phosphorylation (Kim and Yang 2011).
Approximately 1700 proteins, including transcription
factors, signal transduction regulators, and structural
proteins undergo reversible acetylation, which modu-
lates their activity, subcellular localization, and stability
(Choudhary et al. 2009). Posttranslational modification
of proteins by reversible acetylation has therefore
emerged as one of the critical processes in maintaining
cellular homeostasis and shaping responses to environ-
mental stimuli.
Given a central role of protein acetylation in regulat-
ing gene expression at multiple levels, it is not surprising
that several proteins responsible for attachment
(“writers”), recognition (“readers”), and removal
(“erasers”) of acetyl groups are important modulators of
immune responses. Alterations in HAT/HDAC activity and
expression, as well as aberrant histone acetylation marks
have been identified in a number of chronic immune-
mediated inflammatory diseases, including asthma,
chronic obstructive pulmonary disease, colitis, systemic
lupus erythematosus, and rheumatoid arthritis (Grabiec
et al. 2008; Zhang and Zhang 2015). These observations
have generated a great interest in the therapeutic poten-
tial of targeting acetylation regulators and, indeed, inhib-
itors of HDACs have uniformly demonstrated potent
anti-inflammatory properties in vitro in cell types relevant
to pathology of inflammatory disorders and in animal
models of these diseases (Grabiec et al. 2011; Shakespear
et al. 2011). The involvement of sirtuins in immunity, in
particular Sirt1, is more complex and both inhibitors and
activators of sirtuin activity have shown immune modu-
latory effects depending on the model and cell type
tested (Chen et al. 2015). More recently, anti-inflamma-
tory effects of small-molecule acetylated histone mim-
etics, which target BET proteins, have also been reported
(Prinjha et al. 2012; Klein et al. 2016).
Epigenetics of bacterial infections
Characterization of the essential contributions of DNA
and histone modifications in shaping the immune
response, and observations that epigenetic marks are
dynamically regulated by environmental cues have
stimulated interest in the potential roles of epigenetic
mechanisms in microbial infections. Early studies of gas-
tric cancer related to Helicobacter pylori infection identi-
fied alterations in DNA methylation at the promoter
regions of tumor suppressor genes (Maekita et al. 2006).
Although it remains controversial whether aberrant
DNA methylation is directly caused by bacteria or is sec-
ondary to ongoing inflammation, these observations
provided the first proof of principle that epigenetic
changes can be directly linked to bacterial infections.
Subsequent reports found that Escherichia coli,
Campylobacter rectus and Mycobacterium leprae also
regulate DNA methylation patterns and/or DNA methyl-
trasferase expression in host cells (Bobetsis et al. 2007;
Tolg et al. 2011; Masaki et al. 2013). Intriguingly, M. lep-
rae is capable of reprograming differentiated Schwann
cells into stem cell-like cells. These changes are associ-
ated with alterations in DNA methylation and promote
bacillary dissemination (Masaki et al. 2013). These obser-
vations raise the possibility that bacteria can dramatic-
ally alter host cell functions through epigenetic
reprograming of cellular transcriptional programs
(Pereira et al. 2016).
Several enzymatically active bacterial effector mole-
cules have been shown to directly modulate epigenetic
histone marks. The recently discovered examples
include the SET (Suppressor of variegation, Enhancer of
zeste and Trithorax) domain proteins BaSET and BtSET
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produced and delivered into host cells by Bacillus
anthracis and Burkholderia thailandensis, respectively,
which display histone methyltransferase activity (Li, Lu,
et al. 2013; Mujtaba et al. 2013). Upon delivery to the
nucleus, BaSET methylates histone H1, leading to inhib-
ition of NF-jB, whereas BtSET localizes to the nucleolus
and promotes transcription of rRNA genes through
methylation of histone H3K4. Based on these findings,
histone methylation by bacterial effectors has been pro-
posed as a novel virulence strategy and, indeed, SET
domain proteins have been identified in other bacterial
pathogens, including Legionella spp. and Chlamydia
spp. (Rolando et al. 2015).
Bacteria can also modulate epigenetic marks in host
cells indirectly through their effects on mitogen-acti-
vated protein kinase (MAPK) signaling. MAPKs activate
downstream kinases that phosphorylate histone H3S10,
which is associated with H3 acetylation and linked to
activation of transcription (Sawicka and Seiser 2012). B.
anthracis and Mycobacterium tuberculosis have been
shown to modulate MAPK-dependent changes in his-
tone phosphorylation and acetylation, which cause sig-
nificant changes in inflammatory activation of epithelial
cells and macrophages (Pennini et al. 2006; Raymond
et al. 2009). Pathogens can therefore induce epigenetic
changes in host cells through manipulation of signaling
pathways activated during infection, highlighting an
intricate cross-talk between epigenetics and signaling
events that has already been identified in other pathol-
ogies (Grabiec and Reedquist 2013; Singh and
Ellenrieder 2013).
For more detailed discussion of advances in these
areas of patho-epigenetics of microbial infection, we
refer the readers to excellent recent reviews (Bierne
et al. 2012; Rolando et al. 2015; Niller and Minarovits
2016). Here, we will focus on the interactions between
bacteria and the protein acetylation system of the host.
We will discuss the recently discovered strategies used
by pathogenic microorganisms to evade the immune
response through manipulation of histone acetylation
marks, and the effects of compounds that modulate
protein acetylation, in particular HDACi, on the outcome
of bacterial infections.
Bacterial regulation of the host acetylation
system
In recent years, great progress has been made in our
understanding of how bacteria hijack the acetylation
system to manipulate transcriptional regulation in host
cells in order to evade elimination by the immune sys-
tem (Hamon and Cossart 2008; Bierne et al. 2012). A
number of unique mechanisms utilized by pathogenic
microorganisms targeting changes in histone and non-
histone protein acetylation have been identified. They
include direct and indirect effects on epigenetic histone
marks, modulation of HAT and HDAC expression, and
production of metabolites that regulate the activity of
acetylation system components (Table 1).
Modulation of histone acetylation
Several pathogens, including M. tuberculosis, H. pylori
and Listeria monocytogenes have been shown to
manipulate host cell antibacterial responses and evade
the immune system by affecting histone acetylation sta-
tus. Initial evidence that bacteria regulate host gene
expression by altering acetylation of histones was pro-
vided by Wang et al., who demonstrated that M. tuber-
culosis inhibits interferon-c-dependent HLA-DR gene
expression by inducing histone hypoacetylation at the
HLA-DRa promoter (Wang et al. 2005). While M. tubercu-
losis infection had no effect on HDAC1 and HDAC2
expression, it led to upregulation of the corepressor
protein, mammalian Sin3A, which in turn promoted the
formation of an HDAC-containing complex and histone
deacetylation at the promoter region of the HLA-DRa
gene (Wang et al. 2005). Decreased histone acetylation
Table 1. Changes in epigenetic histone acetylation marks and/or expression of acetylation regulators in host cells induced by
pathogenic bacteria.
Bacterial species Bacterial effector Epigenetic effect Reference
Mycobacterium tuberculosis Unknown AcH4 # (Wang et al. 2005)
Helicobacter pylori Unknown AcH3K23 # (Ding et al. 2010)
Listeria monocytogenes Listeriolysin-O AcH3K18 and AcH4 # (Hamon et al. 2007)
InlB AcH3K18 # (Eskandarian et al. 2013)
Legionella pneumophila RomA AcH3K14 # (Rolando et al. 2013)
Anaplasma phagocytophilum Ankyrin A HDAC1 " (Garcia-Garcia et al. 2009)
Pseudomonas aeruginosa 2-Aminoacetophenone HDAC1 " (Bandyopadhaya et al. 2016)
Escherichia coli Proteinase NleC p300 # (Shames et al. 2011)
Porphyromonas gingivalis Unknown HDAC1 and HDAC2 # (Yin and Chung 2011)
SCFAs AcH3, AcH4 " (Imai et al. 2009)
# Reduction of histone acetylation or downregulation of protein expression.
" Induction of histone acetylation or upregulation of protein expression.
AcH: acetylated histone; HDAC: histone deacetylase; SCFAs: short-chain fatty acids.
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levels have also been reported upon infection with H.
pylori (Ding et al. 2010). Chronic infection with H. pylori
is the major cause of human gastric diseases, including
peptic ulcers and malignancies, and alterations in chro-
matin structure have been shown to contribute to the
pathogenic effects of H. pylori on cellular proliferation
and survival (Xia et al. 2008; Fehri et al. 2009). H. pylori-
induced global deacetylation of histone H3K23 in gas-
tric epithelial cells that was accompanied by decreased
histone H3S10 phosphorylation and correlated with dif-
ferential regulation of c-Jun and HSP70 expression
(Ding et al. 2010). The functional consequences of these
changes in epigenetic histone marks, however, have
not been characterized.
Thus far, the most comprehensive mechanistic evi-
dence of bacterial regulation of histone acetylation in
host cells has been provided for the intracellular patho-
gens L. monocytogenes and Legionella pneumophila. L.
monocytogenes, which causes significant morbidity in
pregnant women and newborns, has developed sophis-
ticated strategies to facilitate its entry and survival
within infected cells, among which the manipulation of
the host transcriptional machinery plays an important
role (Niller and Minarovits 2016). Infection of HeLa cells
with L. monocytogenes caused rapid global deacetyla-
tion of histone H4 and specific deacetylation of histone
H3K18 (Hamon et al. 2007; Eskandarian et al. 2013).
Histone H4 deacetylation was associated with reduced
H3S10 phosphorylation, and was dependent on the
virulence factor listeriolysin-O (LLO) (Hamon et al. 2007).
LLO-induced changes in histone modifications strongly
correlated with reduced expression of a small cluster of
host genes, including important regulators of the
immune response (e.g. the chemokine CXCL2 and the
phosphatase DUSP4). Notably, other bacterial toxins
that belong to the same family, perfringolysin from
Clostridium perfringens and pneumolysin from
Streptococcus pneumoniae, had a similar effect on
H3S10 phosphorylation (Hamon et al. 2007). Although
their effects on histone H4 acetylation have not been
tested in this study, it is likely they would be similar to
those generated by LLO given the similarity between
the mechanisms of action of these bacterial effector
molecules.
In contrast, Eskandarian et al. demonstrated that his-
tone H3K18 deacetylation is mediated by the L. monocy-
togenes protein InlB, which activates the receptor c-Met
on host cells (Eskandarian et al. 2013). The signaling cas-
cade triggered by InlB-activated c-Met converged on
nuclear translocation and recruitment of the class III
deacetylase Sirt2 to gene promoter regions. Histone
H3K18 deacetylation by Sirt2 downregulated the
expression of a subset of genes involved in
transcriptional regulation and immune responses,
thereby promoting L. monocytogenes invasion and sur-
vival. The role of Sirt2-dependent transcriptional reprog-
raming during L. monocytogenes infection has been
confirmed in vivo: bacterial titers in infected mice lack-
ing Sirt2 expression were significantly reduced com-
pared to WT mice (Eskandarian et al. 2013). Specific
histone acetylation marks are also reduced in host cells
by L. pneumophila, the etiological factor of severe pneu-
monia called Legionnaires’ disease. The L. pneumophila
effector molecule RomA has been shown to cause tri-
methylation of histone H3K14, which prevents acetyl-
ation of this residue and represses innate immune
genes, such as toll-like receptor 5 (TLR5) and interleu-
kin-6 (IL6) (Rolando et al. 2013). Collectively, these stud-
ies have provided clear biochemical evidence that
pathogenic bacteria utilize a broad range of strategies
targeting epigenetic changes in histone acetylation
to promote their survival within the infected host
(Figure 1).
Manipulation of HDAC expression
An alternative strategy used by many pathogenic bac-
teria to subvert host cell responses utilizes indirect
effects on histone acetylation marks by modulation of
HAT and HDAC expression. In particular, HDAC1 appears
to be the key acetylation system component targeted by
pathogens to evade eradication by the immune system.
Anaplasma phagocytophilum is an intracellular patho-
gen that survives and propagates within neutrophils
and causes human granulocytic anaplasmosis. Because
infection with A. phagocytophilum dramatically alters
major neutrophil functions, involvement of a global epi-
genetic mechanism affecting a broad range of host
defense genes was hypothesized. Indeed, A. phagocyto-
philum upregulated HDAC1 in host cells, causing a glo-
bal increase of HDAC activity (Garcia-Garcia et al. 2009).
The A. phagocytophilum effector molecule ankyrin A
promoted recruitment of HDAC1 to the promoters of
host defense genes which led to a specific reduction of
histone H3 acetylation at these regions and epigenetic
suppression of target gene expression (Garcia-Garcia
et al. 2009; Rennoll-Bankert et al. 2015). Silencing of
HDAC1 expression or inhibition of enzyme activity
restored defense gene expression in infected cells and
prevented intracellular propagation of bacteria (Garcia-
Garcia et al. 2009). Importantly, these effects were spe-
cific for HDAC1, providing evidence that specific
manipulation of a single HDAC family member by
pathogenic microorganisms is sufficient for epigenetic
reprograming of a plethora of host genes required for
protection against infection.
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A similar strategy is used by Pseudomonas aerugi-
nosa, an opportunistic pathogen that typically infects
and colonizes inflamed airways (e.g. in cystic fibrosis)
and burn wounds. The quorum sensing signal released
by P. aeruginosa, 2-aminoacetophenone, induced
expression of HDAC1 in human THP-1 monocytes,
which led to global histone H3K18 hypoacetylation
(Bandyopadhaya et al. 2016). After subsequent chal-
lenge with bacterial molecules, changes in epigenetic
acetylation marks resulted in dampened induction of
inflammatory cytokines and chemokines, including TNF,
IL-1b and MCP-1, thus significantly impairing host cell
responses to infection (Bandyopadhaya et al. 2016).
Similar to A. phagocytophilum infection, these processes
were fully reversible by the HDAC1 knockdown or inhib-
ition of class I HDACs, confirming the central role of
HDAC1 induction in promoting tolerance to
P. aeruginosa through regulation of the host
epigenome.
There is preliminary evidence that the periodontal
pathogen Porphyromonas gingivalis also modulates
expression of HDAC1. Global profiling of HDAC expres-
sion revealed that mRNA and protein levels of HDAC1
are elevated in gingival tissues from patients with
chronic periodontitis compared to healthy controls and
increased expression of HDAC1 colocalizes with TNF-
expressing cells (Cantley et al. 2016). However, this is
likely to be cell type-specific as infection of gingival epi-
thelial cells with oral pathogens in vitro downregulated
HDAC1 and HDAC2 (Yin and Chung 2011), and
increased levels of acetylated histone H3 were detected
in epithelial cells in the gingival tissue in murine peri-
odontitis (Martins et al. 2016). Additional studies are
therefore needed to understand the complex manner in
which P. gingivalis affects HDAC expression in different
types of gingival cells, and whether the differences
reported in patients with periodontitis are caused by
oral pathogenic bacteria or are secondary to the
ongoing chronic inflammation. In this context, it is
important to note that HDAC1 is also upregulated by
cytokines in the absence of infection, and correlates
with expression of inflammatory mediators in synovial
tissue from rheumatoid arthritis patients (Kawabata
et al. 2010; Angiolilli et al. 2016).
The sirtuin family member Sirt1 is also targeted by
bacteria to subvert the host acetylation system. The
intracellular pathogen Salmonella enterica serovar
Typhimurium has been shown to target Sirt1 com-
plexed with regulators of the mTOR pathway to lyso-
somal degradation, which resulted in impairment of
autophagy (Ganesan et al. 2017). Sirt1 was also downre-
gulated in M. tuberculosis-infected macrophages,
Figure 1. Microbial pathogens developed multiple strategies to evade the immune response through manipulation of the host
acetylation system. 2-Aminoacetophenone, a quorum sensing molecule released by Pseudomonas aeruginosa induces HDAC1
expression in host cells (Bandyopadhaya et al. 2016). Similarly, Anaplasma phagocytophilum, through its effector molecule ankyrin
A upregulates HDAC1 and promotes HDAC1 recruitment to gene promoters (Garcia-Garcia et al. 2009; Rennoll-Bankert et al.
2015). The metalloproteinase NleC produced by enteropathogenic and enterohaemorrhagic Escherichia coli degrades the host HAT
p300 (Shames et al. 2011), whereas listeriolysin-O secreted by Listeria monocytogenes promotes histone deacetylation in infected
cells through an unknown mechanism (Hamon et al. 2007). RomA, the effector molecule of Legionella pneumophila, blocks acetyl-
ation by inducing histone H3 trimethylation (Rolando et al. 2013). All these processes lead to global or promoter-specific histone
hypoacetylation, condensation of chromatin structure, and suppressed transcription of genes responsible for host defense against
microbial infection. 2-AA: 2-aminoacetophenone; Ac: acetylated; 3-Me: tri-methylated; LLO: listeriolysin-O; TF: transcription factor.
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promoting intracellular growth of bacteria and persist-
ent inflammatory response. Consistently, Sirt1 activators
reduced lung pathology in mice infected with
M. tuberculosis, whereas deletion of myeloid Sirt1
increased susceptibility to infection (Cheng et al. 2017).
This effect was specific for Sirt1 as myeloid Sirt2 dele-
tion had no effect on chronic M. tuberculosis infection
(Cardoso et al. 2015). In contrast, mice lacking Sirt1 in
myeloid cells had similar mortality upon infection with
Streptococcus pneumoniae as wild-type mice (Crotty
Alexander et al. 2013), indicating a unique role Sirt1 in
host responses to certain intracellular pathogens.
Notably, downregulation of Sirt1 by pathogenic bacteria
modulated host cell responses through changes in the
acetylation status of transcription factors and signaling
molecules (Cheng et al. 2017; Ganesan et al. 2017).
These observations confirmed that subversion of the
host acetylation system by bacteria dysregulates anti-
microbial host responses also through non-epigenetic
mechanisms.
Pathogenic bacteria also manipulate epigenetic regu-
latory mechanisms of the host through proteolytic deg-
radation of a HAT family member. Enteropathogenic
and enterohaemorrhagic E. coli effector protein NleC is
a zinc-dependent metalloproteinase that is delivered to
host cells and targets intracellular signaling to suppress
the inflammatory response. NleC has been shown to
specifically bind and degrade the host HAT p300, which
dampens IL-8 production by infected cells (Shames
et al. 2011). Overexpression of p300 antagonized NleC-
dependent IL-8 suppression by enteropathogenic E. coli
(Shames et al. 2011), confirming that microbial patho-
gens can target both arms of the host histone acetyl-
ation system – HATs and HDACs – to manipulate the
inflammatory response through epigenetic reprogram-
ing (Figure 1).
HDAC inhibition by short chain fatty acids
Pathogenic as well as commensal bacteria can also
modulate the host cell acetylation system through their
metabolic products. Short chain fatty acids (SCFAs),
which are the main fermentation products of anaerobic
bacteria, are potent inhibitors of class I/II HDACs and
regulate multiple aspects of the immune response
(Corre^a-Oliveira et al. 2016). Recent studies have
revealed central roles of SCFAs, such as butyric acid or
propionic acid, in mediating communication between
commensal bacteria and the host immune system.
Commensal microbes promote generation of regulatory
T cells (Tregs) in mice by releasing SCFAs which prevent
exaggerated inflammatory responses in the gut and
thus maintain intestinal immune homeostasis (Arpaia
et al. 2013; Furusawa et al. 2013). Butyrate treatment
enhanced histone H3 acetylation at the promoter
region of the transcription factor FoxP3 (Furusawa et al.
2013), which is critical for Treg differentiation, suggest-
ing involvement of an epigenetic mechanism. The sup-
pressive role of multiple HDAC family members in
FoxP3 induction has been well-documented (Beier et al.
2012) and, in line with this model, only SCFAs capable
of inhibiting HDAC activity potentiated the generation
of Tregs (Arpaia et al. 2013). Modulation of the host
acetylation system by bacterial metabolites can there-
fore be seen as a novel mechanism of host-microbe
interactions, which balances pro- and anti-inflammatory
signals in the mucosal tissue of the gut. Although a
functional link between metabolite production by com-
mensal microbiota and epigenetic regulation in host
cells has only been provided for SCFAs, several other
microbial metabolites can potentially modulate host
epigenetic mechanisms. These include vitamins, isothio-
cyanates, polyphenols, and choline (Krautkramer et al.
2017). Commensal bacteria have also been shown to
induce epigenetic reprograming in mucosal immune
cells through changes in DNA and histone methylation,
though the underlying mechanisms remain to be char-
acterized (Woo and Alenghat 2017).
Whereas SCFAs are clearly beneficial for maintaining
the homeostatic balance between the commensal
microbiota of the intestine and the host, high concen-
trations of these bacterial metabolites may contribute
to pathology during bacterial infections through their
effects on neutrophils and structural cells of the
infected tissue. For example, SCFAs impaired the
effector functions of neutrophils infected with
Aggregatibacter actinomycetemcomitans (Corre^a et al.
2017), an opportunistic facultative anaerobic pathogen
involved in aggressive periodontitis. SCFA treatment
suppressed neutrophil cytokine production, bacterial
phagocytosis and killing of A. actinomycetemcomitans
both in vitro and in vivo. These effects were associated
with histone H3K9 hyperacetylation and most likely can
be attributed to HDAC inhibition by SCFAs.
Consistently, the HDAC inhibitors SAHA and MS-275 dis-
abled neutrophil functions to a similar degree (Corre^a
et al. 2017). SCFAs produced by oral pathogens could
also affect gingival tissue cells to perpetuate inflamma-
tion and alveolar bone resorption in periodontal dis-
ease. Large quantities of butyric acid and propionic acid
are present in gingival crevices of patients with severe
periodontitis, and SCFA concentrations correlate with
clinical parameters of disease activity and inflammation
(Niederman et al. 1996, 1997). In vitro, butyric acid has
been shown to inhibit proliferation and/or induce apop-
tosis of gingival epithelial cells and fibroblasts (Tsuda
CRITICAL REVIEWS IN MICROBIOLOGY 341
et al. 2010; Chang et al. 2013). Although the contribu-
tion of HDAC inhibitory activity of SCFAs to the
reported anti-proliferative effects has not been eval-
uated in these studies, the ability of HDACi to upregu-
late cell cycle inhibitors and induce cell cycle arrest
under inflammatory conditions is well documented
(Nishida et al. 2004; J€ungel et al. 2006).
SCFAs produced by oral pathogens may also contrib-
ute to other pathologies associated with periodontal
disease through their ability to reactivate latent viruses
and induce lytic replication, thus contributing to sys-
temic dissemination of viruses. SCFAs from P. gingivalis
enhanced replication of Epstein-Barr virus (EBV),
Kaposi’s Sarcoma-associated herpesvirus (KPHV), and
human immunodeficiency virus (HIV), and these effects
were dependent on epigenetic changes in histone
acetylation induced by SFCAs (Imai et al. 2009, 2012; Yu
et al. 2014). In that regard, it is noteworthy that the abil-
ity of HDAC inhibitors to reactivate latent viruses can
also be used to the patients’ benefit: HDAC inhibitors
are currently tested as a pharmacological strategy to
purge HIV from its latent reservoir in memory CD4 T
cells (Matalon et al. 2011). The presence of this replica-
tion-competent provirus reservoir is considered the
main obstacle to HIV eradication and the HDAC inhibi-
tor SAHA has been demonstrated to disrupt HIV latency
in vivo in patients on antiretroviral therapy (Archin et al.
2012).
HDAC inhibitors and bacterial infections
HDAC inhibitor effects on immune cell responses
HDAC inhibitors have been thoroughly tested in mul-
tiple models of chronic inflammatory diseases, showing
protective effects in both prophylactic and therapeutic
protocols (Dinarello et al. 2011; Grabiec et al. 2011).
Anti-inflammatory effects of HDAC inhibitors have also
been reported in models of lethal septic shock induced
by systemic administration of LPS or Pam3CSK4 (Ciarlo
et al. 2013). Comparatively little is known about the
effects of these compounds in microbial infections. In
light of the well-established ability of HDAC inhibitors
to suppress cytokine production in response to inflam-
matory agonists, including TLR ligands, questions
regarding the influence of these compounds on the
quality of immune responses to pathogens have arisen.
In a pioneering study addressing this problem, Roger
et al. demonstrated that the HDAC inhibitor valproate
increases mortality of mice after non-severe infection
with Klebsiella pneumoniae or Candida albicans (Roger
et al. 2011). In vitro, HDAC inhibitors impaired a broad
range of innate immune responses of mouse bone
marrow-derived macrophages (BMDMs) and dendritic
cells induced by TLR ligands and other bacterial prod-
ucts (Roger et al. 2011). Phagocytosis and killing of E.
coli and Staphylococcus aureus by BMDMs was also
reduced by HDAC inhibition and associated with
decreased production of reactive oxygen and nitrogen
species (Mombelli et al. 2011). These observations sug-
gested that therapeutic application of HDAC inhibitors
might significantly compromise the immune system
and render patients more susceptible to bacterial
infections.
However, subsequent studies revealed that the
effects of HDAC inhibitors on antibacterial responses in
vitro and in vivo strongly depend on compound select-
ivity and the timing of treatment. Whereas priming with
SAHA or trichostatin A (TSA) impaired phagocytosis of
E. coli by human macrophages, HDAC inhibitor co-treat-
ment had no effect on this process. Instead, simultan-
eous treatment with HDAC inhibitors promoted
clearance of intracellular bacteria by enhancing gener-
ation of mitochondrial reactive oxygen species.
Interestingly, only the HDAC6-specific inhibitor tubasta-
tin A, but not MS-275, which targets only class I HDACs,
improved bacterial killing by macrophages (Ariffin et al.
2015), indicating a unique and non-redundant role for
HDAC6 in this process. The importance of HDAC6 in
anti-bacterial responses by innate immune cells is sup-
ported by observations in the cecal ligation and punc-
ture (CLP)-induced lethal sepsis model. Consistent with
in vitro observations, tubastatin A improved the survival
of animals after CLP, which was associated with
improved bacterial clearance from the blood, attenu-
ated acute liver injury and reduced systemic cytokine
levels, whereas class I HDAC-selective MS-275 had no
effect (Li et al. 2015). HDAC6 inhibition also restored
innate immune cell populations in the bone marrow,
including macrophages and neutrophils, after CLP-
induced sepsis (Zhao et al. 2016). A similar specificity
has been reported in B. anthracis infections: the HDAC8-
specific inhibitor PCI-34051, but not other isoform-
selective HDAC inhibitors, reversed the inhibitory effect
of the Anthrax lethal toxin (LeTx) on IL-1b production
and overcame the resistance of mouse macrophages to
LeTx-induced pyroptosis (Ha et al. 2014, 2016). These
observations suggested that HDAC8 inhibition could
partly restore immune cell functions during B. anthracis
infection. Taken together, these results indicate that
whereas global inhibition of HDAC activity might impair
innate immune responses, selective targeting of individ-
ual HDACs could facilitate elimination of certain micro-
bial pathogens (Figure 2).
Modulators of sirtuin activity have also been tested
in animal models of septic shock. In line with immune
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regulatory role of sirtuins, Sirt1 activation with resvera-
trol attenuated sepsis-induced acute kidney and lung
injury (Li, Zhang, et al. 2013; Xu et al. 2016), whereas
inhibition of Sirt1 during the hypoinflammatory phase
of sepsis reversed endotoxin tolerance and enhanced
immune responses (Vachharajani et al. 2014). It is
important to note, however, that anti-inflammatory
effects of sirtuin inhibition in sepsis have also been
demonstrated. Administration of sirtinol and cambinol,
which inhibit Sirt1 and Sirt2, prior to infection improved
survival of mice during septic shock induced by
K. pneumoniae challenge, which was associated with
suppressed inflammatory activation of immune cells
(Lugrin et al. 2013). The balance between pro- and anti-
inflammatory functions of sirtuins therefore likely
depends on the experimental model, timing of treat-
ment, and/or compound specificity.
HDAC inhibitors in infection-related bone loss
In vivo studies provided evidence that HDAC inhibitors
not only modulate inflammatory responses but may
Figure 2. HDAC inhibitors regulate activation of several cell types involved in antimicrobial responses. Activation of inflammatory
potential of macrophages is suppressed by inhibitors of class I/II HDACs, but specific inhibition of HDAC6 and HDAC8 facilitates
elimination of certain pathogens. SCFAs produced by bacteria and class II HDAC inhibitors stimulate regulatory T cells, which pro-
tect the commensal microbiota from elimination by the immune system but could result in blunted immune response to patho-
genic microorganisms. Similarly, SCFAs and HDAC inhibitors impair antimicrobial responses of neutrophils. Different classes of
HDAC inhibitors and SCFAs stimulate epithelial cell production of CAMPs which contribute to pathogen elimination and stimulate
the host immune response. HDAC inhibitors and BET protein inhibitors also prevent infection-related bone resorption by suppress-
ing osteoclast function. CAMPs: cationic antimicrobial peptides; HDACi: HDAC inhibitors; ROS: reactive oxygen species; SCFAs: short
chain fatty acids; Tregs: regulatory T cells.
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also prevent other pathological consequences of micro-
bial infection, namely alveolar bone loss in periodontitis.
Enhancement of osteoclast activity is an important fea-
ture of chronic inflammation in patients with periodon-
tal disease that contributes to alveolar bone resorption
and eventual tooth loss. The HDAC inhibitor 1179.4b
which targets both class I and class II enzymes, pro-
tected mice from alveolar bone destruction in the
P. gingivalis-induced model of periodontitis (Cantley
et al. 2011). The observed effects can be attributed to
class II HDAC family members as MS-275, which select-
ively targets class I HDACs, failed to protect mice from
bone loss in this model. Surprisingly, alleviated alveolar
bone resorption in 1179.4b-treated animals was not
accompanied by reduced infiltration of immune cells to
the periodontal tissue (Cantley et al. 2011), indicating
that direct suppression of osteoclast formation rather
than global suppression of the inflammatory response
or bacterial outgrowth is responsible for the protective
effects of HDAC inhibition. Indeed, HDAC inhibitors
block osteoclast differentiation in vitro and suppress
osteoclastogenesis in vivo (Rahman et al. 2003;
Nakamura et al. 2005).
Interestingly, targeting different components of the
acetylation system with the BET protein inhibitor JQ1
not only ameliorated alveolar bone resorption and
reduced osteoclast formation in experimental
P. gingivalis-induced periodontitis but also suppressed
expression of inflammatory cytokines in the periodontal
tissue (Meng et al. 2014). These observations suggest
that the blockade of “readers”, rather than “erasers” of
protein acetylation, might be more beneficial in simul-
taneous targeting of both inflammation and bone
resorption in periodontal disease. However, contribu-
tions of individual HDAC isoforms to these processes, as
well as the influence of acetylation modulators on bac-
terial clearance and plaque formation in periodontitis
models remain to be determined.
Regulation of antimicrobial peptide production by
HDAC inhibitors
While previous reports predominantly focused on the
influence of blocking HDAC activity on immune cell
function during infection, studies analyzing epithelial
cell responses to bacterial challenges have identified
HDAC inhibitors as potent regulators of antimicrobial
peptide production (Yedery and Jerse 2015)
(Figure 2). Cationic antimicrobial peptides (CAMPs) are
small (typically<10 kDa) effector molecules of the
immune system that display microbicidal activity
against a broad range of invading pathogens and
modulate both innate and adaptive immune
responses. Large quantities of CAMPs are produced
by epithelial cells of mucosal tissues, which are the
first line of interaction with pathogenic microorgan-
isms (Doss et al. 2010).
Expression of the two major classes of mammalian
CAMPs, defensins, and cathelicidins, is potently induced
by HDAC inhibitors in colonic and airway epithelial cells
(Schauber et al. 2003; Steinmann et al. 2009; Liu et al.
2013; Fischer et al. 2016; Miraglia et al. 2016). Although
CAMP induction by HDAC inhibitors belonging to differ-
ent chemical classes, including TSA, butyrate, phenylbu-
tyrate, and MS-275, has been consistently observed
across different types of epithelial cells (Table 2), several
mechanisms underlying these effects have been pro-
posed. Fischer er al. demonstrated that TSA upregulates
human b-defensin 2 (hBD2) in the colonic epithelial cell
line Caco-2 through a mechanism that involves phos-
phorylation of the IKKa/b complex, acetylation of the
NF-jB p65 subunit and preferential phosphorylation of
histone H3S10 at the hBD2 promoter (Fischer et al.
2016). In contrast, induction of the cathelicidin LL-37 by
SCFAs has been shown to be dependent on MAP kinase
signaling: both ERK and JNK inhibition prevented LL-37
upregulation by phenylbutyrate in bronchial epithelial
cells (Steinmann et al. 2009), and ERK inhibition sup-
pressed induction of LL-37 by butyrate and TSA in
colonic epithelial cells (Schauber et al. 2003). Finally, a
recent study utilized a luciferase-based reporter system
to identify the involvement of the transcription factors
STAT3 and HIF-1a in LL-37 upregulation by MS-275 in
the colonic epithelial cell line HT-29 (Miraglia et al.
2016). It is currently unknown whether changes in the
acetylation status of STAT3 and HIF-1a are responsible
for LL-37 induction, but it is likely to be the case given
that reversible acetylation affects transcription factors in
multiple ways, including their stability, nuclear retention
and gene target specificity (Glozak et al. 2005). While
these studies support the mechanistic model in which
HDAC inhibitors promote CAMP production though
their direct effects on signaling pathways and transcrip-
tion factors, it remains to be verified whether the
observed distinct mechanisms of CAMP induction are
specific for individual CAMP genes, or rather represent a
cell type-specific phenomenon.
The functional importance of CAMP induction by
SCFAs has been validated in vivo in a model of bacillary
dysentery caused by Shigella flexneri. Oral administra-
tion of butyrate reduced the severity of colon inflamma-
tion and bacterial load in the stool of infected rabbits
(Raqib et al. 2006). Improvement of shigellosis clinical
symptoms in butyrate-treated animals was associated
with increased expression of cathelicidin CAP-18 (homo-
logue of LL-37 in rabbits) in the intestinal epithelium
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and accumulation of the active form of CAP-18 in the
stool (Raqib et al. 2006). Based on these findings, a
clinical trial analyzing the effects of butyrate as an
adjunct to antibiotics in patients with shigellosis has
been launched in Bangladesh (ClinicalTrials.gov:
NCT00800930). Compared to placebo, butyrate treat-
ment led to early improvement of rectal inflammation,
reduction of IL-8 and IL-1b levels in the stool, and ele-
vated expression of LL-37 in rectal epithelial cells (Raqib
et al. 2012). Although the contribution of butyrate
HDAC inhibitory activity to the observed effects has not
been tested in this setting, this is the first proof-of-con-
cept study showing that induction of CAMPs by SCFAs
might be clinically beneficial in the treatment of infec-
tions caused by a pathogen that is frequently found to
be antibiotic resistant (Mandomando et al. 2009).
Conclusions and future perspectives
Clear evidence has been provided in the last decade
that protein acetylation in host cells is dynamically
regulated during infection and plays a crucial role in
mounting an effective immune response against patho-
gens. Pathogenic microorganisms developed sophisti-
cated strategies of immune evasion and the host
acetylation system has emerged as an important target
of bacterial virulence factors (Table 1, Figure 1). Thus
far, however, experimental efforts have predominantly
focused on changes in epigenetic histone acetylation
marks induced by bacteria and their transcriptional
consequences. Future studies should therefore be
extended to non-histone targets of HATs and HDACs to
generate a more comprehensive map of changes in the
host acetylome during infection. In that regard, it is
noteworthy that HATs and HDACs also regulate other
types of histone lysine acylations, such as crotonylation
and butyrylation (Sabari et al. 2017), but the role of
these modifications in host–microbe interactions
remains to be investigated. Another pressing question
that remains to be answered is whether changes in his-
tone acetylation (or other epigenetic mechanisms) can
be maintained in host cells after pathogen clearance
Table 2. Studies of histone deacetylase inhibitors (HDACi) in microbial infections.
Compound HDAC specificity Effect Reference
SAHA Class I and II Suppression of neutrophil antimicrobial responses to
A. actinomycetemcomitans
(Corre^a et al. 2017)
Enhancement of ROS production and improvement of
bacterial clearance by macrophages after co-treatment
with bacteria
(Ariffin et al. 2015)
TSA Class I and II Impairment of cytokine production by macrophages and
DCs stimulated with bacterial products
(Roger et al. 2011)
Reduction of bacterial phagocytosis and killing by
macrophages after HDACi pretreatment
(Mombelli et al. 2011)
Enhancement of ROS production and improvement of
bacterial clearance by macrophages after co-treatment
with bacteria
(Ariffin et al. 2015)
Induction of CAMP expression in colonic and gingival
epithelial cells
(Schauber et al. 2003; Yin and Chung
2011; Fischer et al. 2016)
1179.4b Class I and II Reduction of alveolar bone resorption in P. gingivalis-
induced periodontitis in mice
(Cantley et al. 2011)
MS-275 Class I Suppression of neutrophil antimicrobial responses to
A. actinomycetemcomitans
(Corre^a et al. 2017)
Induction of CAMP expression in colonic epithelial cells (Miraglia et al. 2016)
Tubastatin A HDAC6 Improvement of bacterial killing by macrophages after
co-treatment with bacteria
(Ariffin et al. 2015)
Restoration of immune cell populations in the bone
marrow, reduction of mortality in CLP-induced sepsis
in mice
(Li et al. 2015; Zhao et al. 2016)
PCI-34051 HDAC8 Restoration of IL-1 production by macrophages exposed
to LeTx
(Ha et al. 2016)
Butyrate Class I, IIa Induction of CAMP expression in colonic and gingival
epithelial cells
(Schauber et al. 2003; Yin and Chung
2011)
Amelioration of dysentery symptoms and bacterial loads
in rabbits
(Raqib et al. 2006)
Improvement of rectal inflammation in patients with
shigellosis
(Raqib et al. 2012)
Phenyl-butyrate Class I, IIa Induction of CAMP expression in bronchial epithelial cells (Steinmann et al. 2009)
Valproate Class I, IIa Reduction of bacterial phagocytosis and killing by macro-
phages after HDACi pretreatment
(Mombelli et al. 2011)
Impairment of cytokine production by macrophages and
DCs stimulated with bacterial products, reduction of
mouse survival after non-severe infection with
Klebsiella pneumoniae or Candida albicans
(Roger et al. 2011)
CAMP: cationic antimicrobial peptide; CLP: cecal ligation and puncture; DC: dendritic cell; ROS: reactive oxygen species; SAHA: suberoylanilide hydroxamic
acid; TSA: trichostatin A.
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and resolution of inflammation. Although long-lasting
effects of pathogen-induced epigenetic changes remain
largely understudied, the concept of epigenetic mem-
ory of bacterial infection has been supported by some
recent examples (Pereira et al. 2016), as well as the dis-
covery of macrophage “innate immune memory” that is
mediated through epigenetic reprograming (Saeed
et al. 2014).
In light of our increasing knowledge regarding the
many roles of protein acetylation in immunity, the intro-
duction of HDAC inhibitors into clinical practice in
oncology has raised questions about potential risks of
increased sensitivity to infections in HDAC inhibitor-
treated patients. Although infections were commonly
reported in patients with cutaneous T-cell lymphoma
treated with HDAC inhibitors (Piekarz et al. 2009), most
of these adverse events could be attributed to disease-
related impairment of cellular immunity rather than dir-
ect effects of these compounds on the immune system.
Similarly, the risk for infections was not increased in
patients with graft-versus-host disease after hemopoi-
etic stem-cell transplantation treated with SAHA (vori-
nostat) (Choi et al. 2014), suggesting that HDAC
inhibition has no detrimental effects on the quality of
immune responses to infection. Long-term effects of
epigenetic therapies on the immune system, however,
remain to be determined.
Finally, it is important to note that in most cases
manipulation of the protein acetylation system in host
cells by specific pathogens has not been studied in the
context of global effects of acetylation modulators
(HDAC inhibitors, BET inhibitors) on the quality of
immune responses to a broad range of different patho-
gens (Figure 2). Future studies need to be rationally
designed to simultaneously analyze both aspects of
acetylation biology of infections. Only integration of
these two lines of experimental evidence will allow pre-
diction whether pharmacological modulators of the
acetylation system can be used as a therapeutic strat-
egy to promote the pathogen elimination or shape the
immune response to prevent excessive collateral dam-
age of host tissues.
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